Announcements Trials
Browse Landscape

Phase

Phase 2 5Phase 2/3 1Phase 1/2 1Phase 1 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1Endocrine 1

Conditions

Neuroendocrine Tumors 43Carcinoma, Neuroendocrine 22Small Cell Lung Carcinoma 13Carcinoma, Non-Small-Cell Lung 12Neoplasms 11Sarcoma 10Lung Neoplasms 9Thyroid Carcinoma, Anaplastic 7Thyroid Cancer, Papillary 7Stomach Neoplasms 7Pheochromocytoma 7Paraganglioma 7Head and Neck Neoplasms 7Gastro-enteropancreatic neuroendocrine tumor 7Carcinoid Tumor 7Thyroid Neoplasms 6Neoplasm Metastasis 6Colorectal Neoplasms 6Ovarian Neoplasms 5Breast Neoplasms 5Uterine Cervical Neoplasms 4Thyroid Diseases 4Thoracic Neoplasms 4Respiratory Tract Neoplasms 4Respiratory Tract Diseases 4Prostatic Neoplasms 4Neuroblastoma 4Neoplasms by Site 4Multiple Endocrine Neoplasia Type 1 4Lung Diseases 4

Interventions

cediranib 1Lenalidomide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Thyroid cancer, Hurthle cell × Endocrine × Clear all
NCT01208051 2021-07-15

Cediranib Maleate With or Without Lenalidomide for the Treatment of Thyroid Cancer

National Cancer Institute (NCI)

Phase 1/2 Completed
127 enrolled 18 charts
EndocrineHead & Neck

Thyroid cancer, Hurthle cell, Thyroid Cancer, Papillary, Adenocarcinoma, Follicular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡